AFM
SLNO

Anson Funds Management’s Soleno Therapeutics SLNO Stock Holding History

Anson Funds Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-130,000
Closed -$8.79M – 161
2025
Q3 		$8.79M Buy
+130,000
New +$9.64M 0.8% 27

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Anson Funds Management's SLNO Position: Q1 2026 in Review

Anson Funds Management opened a new position in Soleno Therapeutics (SLNO) in Q1 2026: 88,462 shares worth $2.96M. The stake represents 0.13% of the portfolio and ranks #95 among its holdings. This is a return to the name: Anson Funds Management previously reported a position in SLNO as recently as Q4 2016.

Anson Funds Management first reported a position in SLNO in Q4 2016 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Anson Funds Management held 88,462 shares of Soleno Therapeutics worth $2.96M as of Q1 2026.
  • Soleno Therapeutics was a new Anson Funds Management position in Q1 2026.
  • Soleno Therapeutics made up 0.13% of Anson Funds Management's portfolio in Q1 2026, its #95 holding.
  • Anson Funds Management first reported a position in Soleno Therapeutics in Q4 2016 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Anson Funds Management's 13F filing for Q1 2026, filed 14 May 2026.